New Thrombotic Events in Ischemic Stroke Patients with Elevated Factor VIII
Table 1
Baseline characteristics of patients with and without elevated FVIII.
Normal Factor VIII (0.50–1.50 IU/mL) ( = 95)
Elevated Factor VIII (>1.50 IU/mL) ( = 203)
value
Age, median (range)
52 (26–85)
54 (19–90)
0.2908
Gender, % female
43 (45.3%)
108 (53.2%)
0.2015
Black race, %
54 (56.8%)
161 (79.3%)
<0.0001
Past medical history, %
Coronary artery disease
18 (18.9%)
46 (22.7%)
0.4670
Diabetes
16 (17%)
83 (41.3%)
<0.0001
Hypertension
68 (72.3%)
152 (75.3%)
0.5940
Dyslipidemia
25 (26.6%)
76 (37.6%)
0.0625
Atrial fibrillation
2 (2.1%)
7 (3.5%)
0.5284
Prior stroke event
32 (33.7%)
88 (43.3%)
0.2129
Cancer
8 (8.4%)
11 (5.5%)
0.3284
Baseline NIHSS, median (range)
5 (0–24)
5 (0–33)
0.1666
Baseline laboratory values
Glucose, median mmol/L (range)
5.94 (4.16–18.20)
6.72 (3.22–46.12)
0.0033
INR, median (range)
1 (0.7–3.8)
1 (0.8–3.1)
0.3625
IV tPA, %
47 (49.5%)
59 (29.1%)
0.0006
Active smoker, %
43 (46.2%)
69 (34.5%)
0.0543
Home medications, %
Any antithrombotic
33 (34.7%)
74 (36.5%)
0.7735
Any antiplatelet
32 (33.7%)
69 (34.7%)
0.8673
Any anticoagulant
1 (1.1%)
8 (4.2%)
0.1275
TOAST
0.0007
Cardioembolic
11 (11.6%)
39 (19.3%)
Large vessel disease
14 (14.7%)
34 (16.8%)
Small vessel disease
14 (14.7%)
21 (10.4%)
Cryptogenic (>1 cause)
3 (3.2%)
16 (7.9%)
Cryptogenic (no cause found)
40 (42.1%)
44 (21.8%)
Other
9 (9.9%)
45 (22.6%)
Hospital medications, %
Any inpatient antiplatelet
85 (89.5%)
189 (93.1%)
0.2833
Chemical DVT ppx
75 (78.9%)
159 (78.7%)
0.9632
Any full-dose anticoagulant
15 (15.9%)
57 (28.2%)
0.0221
NIHSS indicates National Institutes of Health Stroke Scale; IQR, interquartile range; INR, international normalized ratio; IV tPA, intravenous tissue plasminogen activator; TOAST, trial of ORG 10172 in Acute Stroke Treatment; DVT ppx, deep vein thrombosis prophylaxis. Prior stroke event was confirmed by either patient report or neuroimaging.
